Billed as the world’s most influential technology event, this year’s CES show saw its first ever keynote from a healthcare company when Abbott CEO Robert Ford took to the stage in Las Vegas
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.